Medical Need Europe announced today that it has entered into a license agreement with QOL Medical relating to the product Sucraid® in Europe. Sucraid® is the only available enzyme replacement therapy for individuals with a rare inherited disorder called Congenital Sucrase-Isomaltase Deficiency (CSID). Sucraid® is approved as an orphan drug in the US. Under the agreement, Medical Need Europe will act as the exclusive distributor for the product in large parts of Europe, including all EU member states, Norway, Iceland, Switzerland, Greenland and Turkey. The parties intend to collaborate regarding a regulatory approval for the product in the Territory. Presently, Sucraid® is prescribed on a Named Patient Basis across Europe.
About CSID and Sucraid®
CSID is an inherited inborn error of metabolism caused by a malfunctioning or missing enzyme in the gut. Patients with CSID have an inability to degrade and absorb certain sugars in the food, causing symptoms including failure to thrive, severe diarrhoea, stomach cramps. Sucraid® (sacrosidase), taken in connection with meals, replaces the missing enzyme and restores the ability to degrade and absorb table-sugar. More information on the product can be found on the US homepage www.sucraid.net.
About QOL Medical
QOL Medical is a specialty biopharmaceutical company dedicated to improving the quality of life for patients with rare diseases, for their families, and for the physicians and caregivers who support them. The Company currently markets three FDA-approved products including Sucraid®, Ethamolin®, and Elliotts B® Solution. More information on QOL Medical can be found on www.qolmed.com
About Medical Need
Medical Need is a Sweden based pharmaceutical company, focusing on the registration, distribution, marketing and sale of orphan drugs and niche specialty pharmaceuticals for unmet medical needs in Europe. More information on Medical Need can be found on www.medicalneed.com